Clinical Trials on Refractory Multiple Myeloma

Total 14098 results

Mayo Clinic

Completed

Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma

Plasma Cell Myeloma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Roswell Park Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Fred Hutchinson Cancer Center
The Leukemia and Lymphoma Society; Juno Therapeutics, Inc., a Bristol-Myers...

Terminated

BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH); Millennium... and other collaborators

Active, not recruiting

Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Completed

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Withdrawn

Simvastatin in Overcoming Chemotherapy Resistance in Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Completed

Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Sanofi

Not yet recruiting

A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (SubQSA)

Plasma Cell Myeloma Refractory
University of Colorado, Denver

Terminated

Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant

Refractory Plasma Cell Myeloma

United States
Sanofi

Recruiting

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Plasma Cell Myeloma Refractory

France, Australia, Greece, Italy, Norway, United States, Portugal, Puerto Rico
Novartis Pharmaceuticals

Completed

Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation

Relapsed or Refractory Multiple Myeloma

United States, Turkey, Canada, Netherlands, Australia, Germany, France
University of Heidelberg Medical Center
German Cancer Research Center; University Hospital Heidelberg; Array BioPharma; Coordinating Centre for Clinical Trials Heidelberg

Active, not recruiting

BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA) (GMMG-BIRMA)

Relapsed or Refractory Multiple Myeloma | Patients With BRAFV600 E or BRAFV600K Mutation

Germany
Genmab

Recruiting

GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies

Acute Myeloid Leukemia (AML) | Diffuse Large B Cell Lymphoma (DLBCL) | Relapsed or Refractory Multiple Myeloma (RRMM)

United States, Korea, Republic of, Netherlands, Denmark, Australia, New Zealand, Poland, Spain, Sweden, Czechia, Malaysia, Greece, Moldova, Republic of, Georgia, Ukraine, France, Hungary, North Macedonia
Mayo Clinic
National Cancer Institute (NCI)

Completed

Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Completed

Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Terminated

Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell Transplant

Refractory Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma | DS (Durie/Salmon) Stage I Plasma Cell Myeloma

United States
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Completed

Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Novartis Pharmaceuticals

Active, not recruiting

VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)

Acute Myeloid Leukemia (AML) | Multiple Myeloma (MM) | Non-Hodgkin Lymphoma (NHL)

Belgium, Italy, Korea, Republic of, Hong Kong, Israel, Finland, Spain, Japan, United States
University of Southern California
National Cancer Institute (NCI)

Recruiting

Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Juno Therapeutics, Inc.

Completed

Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
University of Southern California
National Cancer Institute (NCI); Oncolytics Biotech

Completed

Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Yvonne Efebera
Bristol-Myers Squibb; National Cancer Institute (NCI); American Cancer Society...

Terminated

Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Completed

AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Celyad Oncology SA

Unknown

A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK)

Acute Myeloid Leukemia/Myelodysplastic Syndrome | Multiple Myeloma (MM)

United States, Belgium
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma

Plasma Cell Myeloma | Refractory Plasma Cell Myeloma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Unknown

NK Cells in Cord Blood Transplantation

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent Acute Lymphoblastic Leukemia and other conditions

United States
National Cancer Institute (NCI)

Completed

Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Light Chain Deposition Disease

United States
Hangzhou Sumgen Biotech Co., Ltd.

Active, not recruiting

SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies

Relapsed or Refractory Multiple Myeloma | Hematological Malignancy

China
Takeda

Completed

A Study of People With Multiple Myeloma (MM) in Portugal (CharisMMa-Portugal)

Relapse and/or Refractory Multiple Myeloma

Portugal
Intergroupe Francophone du Myelome
Bristol-Myers Squibb; Takeda; University Hospital, Grenoble; Nantes University... and other collaborators

Terminated

IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic (IFM2014-01)

Multiple Myeloma | Genetic Condition | Relapsed and Refractory Multiple Myeloma

France
Genesis Pharma S.A.

Completed

A Retrospective Chart Review Study of the Outcomes of 2nd Line Therapy With LEn/Dex in Greek Patients With R/R Multiple MyEloma and the Treatment PatterNs Following Progressive Disease (LEGEND)

Relapsed/Refractory Multiple Myeloma

Greece
Nanjing IASO Biotechnology Co., Ltd.
Ruijin Hospital

Recruiting

A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Plasma Cell Leukemia | Relapsed/Refractory Multiple Myeloma

China
Chunrui Li
Nanjing IASO Biotechnology Co., Ltd

Recruiting

A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Plasma Cell Leukemia | Relapsed/Refractory Multiple Myeloma

China
Multinational Center for Quality of Life Research...

Unknown

Quality of Life, Symptoms and Treatment Satisfaction in Adult Patients With Relapsed and/or Refractory Multiple Myeloma, Receiving Ixazomib (Ninlaro®) in Combination With Lenalidomide and Dexamethasone in a Real World Setting: Pilot Study

Relapsed and/or Refractory Multiple Myeloma
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Hematopoietic Cell Transplantation Recipient

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Withdrawn

RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Non-Secretory Plasma Cell Myeloma | Plasmacytosis

United States

Clinical Trials on Refractory Multiple Myeloma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Latvia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations